|
WO2021044045A1
|
|
Ophthalmic composition for the treatment of uveitis
|
|
WO2021028328A1
|
|
Topical composition comprising a prostaglandin analogue
|
|
WO2020239646A1
|
|
Ophthalmic composition for the treatment of ocular allergy
|
|
WO2020165132A1
|
|
Compositions and methods for the treatment of ocular neovascularization
|
|
WO2020152046A1
|
|
Pharmaceutical composition for the treatment of ocular neovascularisation
|
|
WO2020109192A1
|
|
Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
|
|
CA3112031A1
|
|
Ophthalmic composition for treatment of dry eye disease
|
|
WO2020064549A1
|
|
Lipid barrier repair
|
|
WO2020058504A1
|
|
Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
|
|
WO2020064556A1
|
|
Topical sunscreen formulation
|
|
WO2019206956A1
|
|
Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
|
|
KR20200136403A
|
|
Pharmaceutical composition containing timolol
|
|
EP3758676A1
|
|
Pharmaceutical compositions comprising nebivolol
|
|
US2020268682A1
|
|
Opthalmic compositions comprising f6h8
|
|
KR20200059272A
|
|
Ophthalmic composition comprising latanoprost for use in the treatment of ocular diseases
|
|
US2020339492A1
|
|
Process for the preparation of semifluorinated alkanes using grignard reagents
|
|
WO2018215638A1
|
|
Pharmaceutical compositions comprising azithromycin
|
|
EP3621601A1
|
|
Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
|
|
EP3619186A1
|
|
Process for the production of semifluorinated alkanes
|
|
EP3618782A1
|
|
Drop dispenser
|
